Can Fite Biopharma Ltd
CANF0.646USD
-0.001-0.08%
Fechamento 09/17, 16:00（ET）Cotações atrasadas em 15 min
2.56BValor de mercado
PerdaP/L TTM
Mais detalhes de Can Fite Biopharma Ltd Empresa
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Informações da empresa
Código da empresaCANF
Nome da EmpresaCan Fite Biopharma Ltd
Data de listagemSep 22, 2005
CEODr. Pnina Fishman, Ph.D.
Número de funcionários5
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 22
Endereço10 Bareket Street, Kiryat Matalon
CidadePETAH TIKVA
Bolsa de valoresTel Aviv Stock Exchange
PaísIsrael
Código postal49170
Telefone97239241114
Sitehttps://www.canfite.com/
Código da empresaCANF
Data de listagemSep 22, 2005
CEODr. Pnina Fishman, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. Sari Fishman, Ph.D.
Dr. Sari Fishman, Ph.D.
Vice President - Business Development
Vice President - Business Development
--
--
Mr. Yoseph Borenstein
Mr. Yoseph Borenstein
Director
Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Yaacov Goldman
Mr. Yaacov Goldman
Independent Director
Independent Director
--
--
Mr. Guy Regev
Mr. Guy Regev
Independent Director
Independent Director
--
--
Dr. Abraham Sartani, M.D.
Dr. Abraham Sartani, M.D.
Independent Director
Independent Director
--
--
Dr. Ilan Cohen
Dr. Ilan Cohen
Chairman of the Board
Chairman of the Board
--
--
Dr. Pnina Fishman, Ph.D.
Dr. Pnina Fishman, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Motti Farbstein
Mr. Motti Farbstein
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Sabby Management, LLC
4.94%
Rhumbline Advisers Ltd. Partnership
0.37%
Abalone Asset Management Ltd.
0.15%
BNP Paribas Securities Corp. North America
0.11%
Two Sigma Investments, LP
0.10%
Outro
94.33%
Investidores
Investidores
Proporção
Sabby Management, LLC
4.94%
Rhumbline Advisers Ltd. Partnership
0.37%
Abalone Asset Management Ltd.
0.15%
BNP Paribas Securities Corp. North America
0.11%
Two Sigma Investments, LP
0.10%
Outro
94.33%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
4.94%
Investment Advisor
0.65%
Research Firm
0.19%
Hedge Fund
0.10%
Outro
94.11%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
29
155.14K
1.06%
-711.63K
2025Q1
30
155.14K
1.17%
-710.63K
2024Q4
28
154.43K
1.51%
-671.86K
2024Q3
26
794.33K
11.46%
+115.72K
2024Q2
26
667.93K
11.77%
+152.94K
2024Q1
24
517.69K
9.97%
+253.94K
2023Q4
29
283.94K
5.78%
+189.77K
2023Q3
28
67.77K
1.66%
-429.92K
2023Q2
28
54.74K
1.34%
-433.22K
2023Q1
31
368.56K
9.03%
+211.26K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Rhumbline Advisers Ltd. Partnership
38.27K
0.29%
+11.39K
+42.37%
Mar 31, 2025
Abalone Asset Management Ltd.
23.81K
0.18%
-16.19K
-40.48%
Jun 30, 2024
BNP Paribas Securities Corp. North America
22.59K
0.17%
-2.60K
-10.32%
Mar 31, 2025
CAPTRUST Financial Advisors
10.63K
0.08%
+10.63K
--
Mar 31, 2025
Morgan Stanley & Co. LLC
23.21K
0.17%
-9.30K
-28.60%
Mar 31, 2025
MainStreet Advisors
3.00K
0.02%
--
--
Mar 31, 2025
Wells Fargo Advisors
2.70K
0.02%
+200.00
+8.00%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Data
Tipo
Proporção
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
Jan 03, 2023
Merger
10→1
